US › Healthcare

CAMP4 THERAPEUTICS CORPORATION (CAMP)

US · Healthcare · Biotechnology

$4.16-1.19%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$1.3M
Revenue YoY
+50.8%
Net profit
$-18.3M
Profit YoY
-47.4%
EPS
$-0.21
EPS estimate
$-0.21
Net margin
-1,416.6%

EPS came in at -0.21 against a street estimate of -0.21 — a beat of 0.0%.

Key statistics

Market cap
$179.1M
Forward P/E
0.0
P/B
5.76
Book value
$0.59
EPS (TTM)
$-2.35
52-week high
$7.75
52-week low
$1.32
50-day MA
$4.04
200-day MA
$4.41

Analyst view

Analysts rate CAMP4 THERAPEUTICS CORPORATION a strong buy (5 buy, 0 hold, 0 sell out of 5) with an average price target of $8.58.

Shareholding

Insiders
13.07%
Institutions
87.25%

Largest institutional holders

FundStake
HHG PLC12.15%
5AM Venture Management, LLC11.30%
FMR Inc9.50%
Vivo Capital, LLC8.18%
Balyasny Asset Management LLC5.07%
Enavate Sciences GP, LLC4.22%
Adage Capital Partners Gp LLC3.78%
Trails Edge Capital Partners, LP3.74%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for CAMP4 THERAPEUTICS CORPORATION — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.